ADVERTISEMENT
Videos
Real-World Study Compares Third and Subsequent Line Regimens for Treating Metastatic Triple-Negative Breast Cancer
07/14/2022
Shlomit Amar-Farkash, PhD, MSc, Anthem Innovation Israel, Tel Aviv, Israel compared the impact of treatment with Eribulin vs other commonly used chemotherapies as third and subsequent lines of therapy on overall survival and post-treatment hospitalizations among patients with metastatic triple-negative breast cancer in the United States.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
June 2024
Volume 10
Issue 3
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Journal of Clinical Pathways Newsletter
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement